CN110194762B - Phthalazinone derivatives, preparation method and application thereof - Google Patents
Phthalazinone derivatives, preparation method and application thereof Download PDFInfo
- Publication number
- CN110194762B CN110194762B CN201810162895.7A CN201810162895A CN110194762B CN 110194762 B CN110194762 B CN 110194762B CN 201810162895 A CN201810162895 A CN 201810162895A CN 110194762 B CN110194762 B CN 110194762B
- Authority
- CN
- China
- Prior art keywords
- pyridyl
- substituted
- cancer
- unsubstituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- -1 cyano, hydroxyl Chemical group 0.000 claims description 85
- 150000001875 compounds Chemical class 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 125000006413 ring segment Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 208000023589 ischemic disease Diseases 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000000302 ischemic effect Effects 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 229910052717 sulfur Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 239000001301 oxygen Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010074063 Ischaemic enteritis Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 125000006378 chloropyridyl group Chemical group 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 11
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 206010059866 Drug resistance Diseases 0.000 description 9
- 239000012661 PARP inhibitor Substances 0.000 description 9
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000006482 condensation reaction Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 229960000572 olaparib Drugs 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000008159 sesame oil Substances 0.000 description 7
- 235000011803 sesame oil Nutrition 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 235000019483 Peanut oil Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000312 peanut oil Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 3
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical group [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 125000001174 sulfone group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- LOWMYOWHQMKBTM-UHFFFAOYSA-N 1-butylsulfinylbutane Chemical group CCCCS(=O)CCCC LOWMYOWHQMKBTM-UHFFFAOYSA-N 0.000 description 1
- AIDFJGKWTOULTC-UHFFFAOYSA-N 1-butylsulfonylbutane Chemical group CCCCS(=O)(=O)CCCC AIDFJGKWTOULTC-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- MBDUIEKYVPVZJH-UHFFFAOYSA-N 1-ethylsulfonylethane Chemical group CCS(=O)(=O)CC MBDUIEKYVPVZJH-UHFFFAOYSA-N 0.000 description 1
- BQCCJWMQESHLIT-UHFFFAOYSA-N 1-propylsulfinylpropane Chemical group CCCS(=O)CCC BQCCJWMQESHLIT-UHFFFAOYSA-N 0.000 description 1
- JEXYCADTAFPULN-UHFFFAOYSA-N 1-propylsulfonylpropane Chemical group CCCS(=O)(=O)CCC JEXYCADTAFPULN-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- LWXNQQIVUUSCSL-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol trihydrochloride Chemical compound Cl.Cl.Cl.OCC(N)(CO)CO LWXNQQIVUUSCSL-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- MCDJZKPTBCWNSJ-UHFFFAOYSA-N 2-methyl-1-(2-methylpropylsulfinyl)propane Chemical group CC(C)CS(=O)CC(C)C MCDJZKPTBCWNSJ-UHFFFAOYSA-N 0.000 description 1
- ULSLZZKKTPQNNJ-UHFFFAOYSA-N 2-methyl-1-(2-methylpropylsulfonyl)propane Chemical group CC(C)CS(=O)(=O)CC(C)C ULSLZZKKTPQNNJ-UHFFFAOYSA-N 0.000 description 1
- IWEYZXWPWNBRLG-UHFFFAOYSA-N 2-methylpropane-1-sulfonamide Chemical group CC(C)CS(N)(=O)=O IWEYZXWPWNBRLG-UHFFFAOYSA-N 0.000 description 1
- GWJSQKNYHPYZRN-UHFFFAOYSA-N 2-methylpropane-2-sulfonamide Chemical group CC(C)(C)S(N)(=O)=O GWJSQKNYHPYZRN-UHFFFAOYSA-N 0.000 description 1
- WFJXYIUAMJAURQ-UHFFFAOYSA-N 2-propan-2-ylsulfinylpropane Chemical group CC(C)S(=O)C(C)C WFJXYIUAMJAURQ-UHFFFAOYSA-N 0.000 description 1
- ZDULHUHNYHJYKA-UHFFFAOYSA-N 2-propan-2-ylsulfonylpropane Chemical group CC(C)S(=O)(=O)C(C)C ZDULHUHNYHJYKA-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- HKKFQOPIRHHEGQ-UHFFFAOYSA-N 2-tert-butylsulfinyl-2-methylpropane Chemical group CC(C)(C)S(=O)C(C)(C)C HKKFQOPIRHHEGQ-UHFFFAOYSA-N 0.000 description 1
- SPJQDMKTFSPPLO-UHFFFAOYSA-N 2-tert-butylsulfonyl-2-methylpropane Chemical group CC(C)(C)S(=O)(=O)C(C)(C)C SPJQDMKTFSPPLO-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- VDOBVQQBEJBNHU-UHFFFAOYSA-N 6-(ethylamino)pyridine-3-carbaldehyde Chemical compound CCNC1=CC=C(C=O)C=N1 VDOBVQQBEJBNHU-UHFFFAOYSA-N 0.000 description 1
- AFWWKZCPPRPDQK-UHFFFAOYSA-N 6-chloropyridine-3-carbaldehyde Chemical compound ClC1=CC=C(C=O)C=N1 AFWWKZCPPRPDQK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 108700010154 BRCA2 Genes Proteins 0.000 description 1
- 206010071981 BRCA2 gene mutation Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical group NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000005619 boric acid group Chemical group 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical group CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- OVIZSQRQYWEGON-UHFFFAOYSA-N butane-1-sulfonamide Chemical group CCCCS(N)(=O)=O OVIZSQRQYWEGON-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical group CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical group CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical group CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- CMWAMJBCWMMGCH-UHFFFAOYSA-N methyl 3-(6-chloropyridin-3-yl)prop-2-enoate Chemical compound COC(=O)C=CC1=CC=C(Cl)N=C1 CMWAMJBCWMMGCH-UHFFFAOYSA-N 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PCJWVQUPHYPGIE-UHFFFAOYSA-N n-butyl-4-methoxybenzamide Chemical group CCCCNC(=O)C1=CC=C(OC)C=C1 PCJWVQUPHYPGIE-UHFFFAOYSA-N 0.000 description 1
- 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical group CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 description 1
- SJMCLWCCNYAWRQ-UHFFFAOYSA-N propane-2-sulfonamide Chemical group CC(C)S(N)(=O)=O SJMCLWCCNYAWRQ-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- WUPVYJJCKYSGCR-UHFFFAOYSA-M sodium;3-oxoisoindol-1-olate Chemical compound [Na+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 WUPVYJJCKYSGCR-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical group CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical group CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229950011257 veliparib Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of pharmaceutical chemistry, and relates to phthalazinone derivatives shown as a general formula (I), geometric isomers or pharmaceutically acceptable salts thereof, a preparation method and application in preparation of medicines for preventing or treating diseases related to poly (adenosine diphosphate ribose) polymerase resistance.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and relates to phthalazinone derivatives, geometric isomers thereof, pharmaceutically acceptable salts thereof, a preparation method thereof and application thereof in preparing medicaments for preventing or treating diseases related to drug resistance of poly (adenosine diphosphate ribose) polymerase (PARP), such as malignant tumors.
Background
Poly (ADP) -ribosepolymerase (PARP) is a family of enzymes found in the nucleus of most eukaryotic cells. Since the first discovery by Chambon et al in 1963, a total of 17 PARP family members have been discovered so far [ riffleljl, et al, natrevdrug discovery 2012; 11:923-936], wherein 7 PARP enzymes including PARP-1 and PARP-2 were characterized and confirmed. The PARP family is a multifunctional protein post-translational modification enzyme, although the function research on the subtype thereof is continuously expanding, because PARP-1/2 is the most abundant ribozyme in the PARP family, and more than 90 percent of DNA damage depends on PARP-1 repair; among PARP-1 deficient cells, PARP-2 is responsible for DNA damage repair.
Bryant 2005 (Nature 2005; 434: 913-; 434: 917-.
Currently, there is already Olapari from AstraZeneca(2014) Lukapari by Clovis OncologyNilaparide tosylate (2016. RTM.) from MoshadongDrugs targeting PARP (2017) are successfully marketed in sequence, and meanwhile, many projects targeting PARP are developed in various stages of clinical research.
With the successful marketing of PARP inhibitors, tumor cell lines resistant to the existing inhibitors have emerged clinically. Tumor resistance is a great problem limiting the curative effect of the current cancer chemotherapy drugs; many cancer patients have significant efficacy in the early stages of chemotherapy, but as treatment time increases, the resistance of cancer cells increases, eventually leading to treatment failure. Researches on the drug resistance of PARP inhibitors and tumor cells have been reported, and Norquist et al [ JClin Oncol,2011,29(22):3008-3015] found in clinical researches that 2 of 6 BRCA gene mutation ovarian cancer patients who are resistant to carboplatin and treated by Olaparib show drug resistance; liu et al [ Mol cancer Res,2009,7(10):1686-1692] studies showed that HCT116 colorectal cancer cells treated with temozolomide in combination with ABT-888 also exhibited drug resistance; researchers have also found that continuous administration of the potent PARP-1 inhibitor KU0058948 to CAPAN1 pancreatic cancer cells with mutations in the BRCA2 gene can cause cancer cell resistance, and that CAPAN1 cells that are resistant to cisplatin also develop resistance to the PARP-1 inhibitor AG 14361; in a mouse breast cancer model with BRCA gene mutation and an inactivated cancer suppressor gene p53, Olaparib treatment is given, the growth of breast cancer can be obviously inhibited at the beginning, however, after long-term administration of treatment, the tumor inhibition effect of Olaparib is gradually weakened [ TrendsPharmacolSci,2012,33(1):42-48 ]; sakai et al [ cancer Res,2009,69(16):6381-6386] found that the ovarian cancer cell strain PEO4 with BRCA2 gene mutation is resistant to PARP-1 inhibitor AG 14361; the mechanism of tumor cell resistance to PARP inhibitors varies depending on the type and stage of cancer and the method of treatment [ NatMed,2013,19(11):1381-1388 ].
With the progress of basic research related to the drug resistance of PARP inhibitors, researchers have proposed many strategies to address the problem of PARP inhibition of drug-resistant tumors. The main of these strategies is the use of PARP inhibitors in combination with other therapeutic approaches. Such as: PARP inhibitors are used in combination with the cytotoxic drugs Temozolomide (Temozolomide), Taxanes, Platinum salts (Platinum salts) and Gemcitabine (Gemcitabine), etc.; PARP inhibitors are used in combination with other targeted inhibitors such as EGFR inhibitors, PI3K inhibitors, HDAC inhibitors, IGF-1R inhibitors, VEGFR inhibitors, HSP90 inhibitors, CHK1/2 inhibitors, and the like; PARP inhibitors in combination with immunotherapy and the like [ Critical Reviews in Oncology/Hematology 108(2016) 73-85 ].
However, there is still a need to develop drugs that can solve the problem of PARP inhibitor resistance.
Disclosure of Invention
The invention provides phthalazinone derivatives shown as a general formula I, geometric isomers and pharmaceutically acceptable salts thereof on one hand,
wherein:
r is selected from H, C1-C6Alkyl (e.g. methyl or ethyl), C2-C6Alkenyl radical, C2-C6An alkynyl group; preferably H or methyl;
n is an integer of 1-6; for example 2 to 5, preferably 4;
het is selected from substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered heterocyclyl, substituted or unsubstituted C6-C12Aryl or substituted or unsubstituted 5-12 membered heteroaryl; the substituted substituent is selected from halogen, nitryl, amino, cyano, hydroxyl and C1-C6Alkyl radical, C2-C6Alkenyl radical, C2-C6Alkynyl, C1-C6Alkoxy, halo C1-C6Alkyl, hydroxy C1-C6Alkyl radical, C1-C6Alkylamino, di-C1-C6Alkylamino radical, C1-C6Alkylsulfonamide group, C1-C6Amide group, C1-C6Acyloxy, C1-C6Alkoxycarbonyl, C1-C6An alkylcarbonyl group,Boric acid group, C1-C6Alkyl sulfone group, C1-C6Alkyl sulfoxide group, C1-C6Alkylmercapto, 3-8 membered cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), 3-8 membered heterocyclyl (e.g., glycidylalkyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl), C6-C10One or more of aryl (e.g., phenyl, naphthyl) and 5-10 membered heteroaryl (e.g., furyl, pyrrolyl, oxazolyl, imidazolyl, pyridyl, pyridazinyl, triazolyl, tetrazolyl, thiazolyl, pyrazinyl, pyrimidinyl, indolyl).
In a preferred embodiment of the present invention, the phthalazinone derivative compound includes a phthalazinone derivative represented by formula ii:
wherein Het is as defined above.
Preferably, Het in the above general formulae I and II is selected from substituted or unsubstituted naphthyl, substituted or unsubstituted five-membered heteroaryl, substituted or unsubstituted six-membered heteroaryl, substituted or unsubstituted five-membered and six-membered heteroaryl; further preferably selected from the group consisting of substituted or unsubstituted thienyl, substituted or unsubstituted indolyl, substituted or unsubstituted naphthyl, substituted or unsubstituted furyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidyl, and substituted or unsubstituted pyrazinyl.
The substituents substituted in the Het definition are preferably selected from halogen, nitro, amino, cyano, hydroxy, C1-C4Alkyl radical, C1-C6Alkoxy, halogen-substituted C1-C4Alkyl, morpholinyl, piperidinyl, pyrrolidinyl, C1-C4One or more of alkylamino groups; or,
wherein X is selected from O, N, S;
Y1and Y2Each independently selected from N or C, but not both.
In a preferred embodiment of the invention, said Het is selected from pyridyl, chloropyridyl, indolyl, pyrrolyl, thiazolyl, pyrimidinyl, aminotrifluoromethylpyridyl, azaindolyl, dimethylisoxazolyl, piperidinylpyridyl, morpholinylpyridyl, pyrrolidinopyridyl, diethylaminopyridyl, ethylaminopyridyl, methylaminopyridyl, naphthyl, aminopyridinyl, benzofuranyl; more preferably 4-pyridyl, 2-chloro-5-pyridyl, 3-indolyl, 2-pyrrolyl, 4-thiazolyl, 5-pyrimidyl, 2-amino-6- (trifluoromethyl) -5-pyridyl, 7-azaindolyl, 3, 5-dimethyl-4-isoxazolyl, 2-piperidyl-5-pyridyl, 2-morpholinyl-5-pyridyl, 2-pyrrolidine-5-pyridyl, 2-diethylamino-5-pyridyl, 2-ethylamino-5-pyridyl, 2-methylamino-5-pyridyl, 1-naphthyl, 6-azaindolyl, 2-pyridyl, 5-pyridyl, 2-pyridyl, etc, 2-amino-5-pyridyl, 3-benzofuranyl and 3-pyridyl.
In another preferred embodiment of the present invention, the phthalazinone derivative is selected from the following compounds:
“C1-C6alkyl "refers to a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms in the chain, including, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, and the like.
“C1-C6Alkylamino "refers to an amino group substituted with a straight or branched alkyl group having 1 to 6 carbon atoms in one chain, and includes, without limitation, methylamino, ethylamino, propylamino, isopropylamino, butylamino, and the like.
' di C1-C6Alkylamino "means an amino group substituted on N by two identical or different straight or branched chain saturated hydrocarbon groups having 1 to 6 carbon atoms, for example, N-dimethylamino, N-diethylamino, N-di-N-propylamino, N-ethyl-N-methylamino, N-methyl-N-propylamino, N-butyl-N-methylamino.
“C1-C6The alkylsulfonamide group "means a straight or branched alkylsulfonamide group having 1 to 6 carbon atoms in the alkyl moiety, for example, a methylsulfonamide group, an ethylsulfonamide group, an n-propylsulfonamide group, an isopropylsulfonamide group, an n-butylsulfonamide group, an isobutylsulfonamide group or a tert-butylsulfonamide group.
“C1-C6The amide group "means a straight or branched alkyl amide group having 1 to 6 carbon atoms in the alkyl moiety, for example, a methyl amide group, an ethyl amide group, an n-propyl amide group, an isopropyl amide group, an n-butyl amide group, an isobutyl amide group or a tert-butyl amide group.
“C1-C6Acyloxy "refers to straight or branched chain alkanoyloxy having 1 to 6 carbon atoms in the alkyl moiety, for example, methacryloyloxy, ethylacetoxy, n-propylacyloxy, isopropylacyloxy, n-butylacyloxy, isobutylacyloxy or tert-butylacyloxy.
“C1-C6Alkylcarbonyl "refers to straight or branched chain alkylcarbonyl having 1 to 6 carbon atoms in the alkyl moiety, for example, methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, isobutylcarbonyl or tert-butylcarbonyl.
“C1-C6Alkoxy "refers to straight or branched chain O-alkyl groups containing from 1 to 6 carbon atoms in the alkyl moiety, for example,methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy.
“C1-C6By alkylmercapto "is meant a straight or branched chain S-alkyl group containing from 1 to 6 carbon atoms in the alkyl moiety, for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio or tert-butylthio.
"Borate" means-B (OH)2。
“C1-C6The alkyl sulfone group "means a straight-chain or branched alkyl sulfone group having 1 to 6 carbon atoms in the alkyl moiety, for example, a methyl sulfone group, an ethyl sulfone group, an n-propyl sulfone group, an isopropyl sulfone group, an n-butyl sulfone group, an isobutyl sulfone group or a tert-butyl sulfone group.
“C1-C6The alkyl sulfoxide group "means a linear or branched alkyl sulfoxide group having 1 to 6 carbon atoms in the alkyl moiety, for example, a methyl sulfoxide group, an ethyl sulfoxide group, an n-propyl sulfoxide group, an isopropyl sulfoxide group, an n-butyl sulfoxide group, an isobutyl sulfoxide group or a tert-butyl sulfoxide group.
“C2-C6Alkenyl "refers to a straight or branched chain alkenyl group having 2 to 6 carbon atoms containing at least one unsaturated carbon-carbon double bond in the chain, including without limitation ethenyl, propenyl, isopropenyl.
“C2-C6Alkynyl "means a straight or branched chain alkynyl group of 2 to 6 carbon atoms containing at least one unsaturated carbon-carbon triple bond in the chain, including, without limitation, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-or 3-butynyl.
"3-8 membered cycloalkyl" refers to a group containing one or more saturated and/or partially saturated rings, all ring-forming atoms being carbon atoms, which includes from 3 to 8 carbon atoms; for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptenyl, cycloheptatrienyl, cyclooctyl, indanyl, tetrahydronaphthyl, benzocycloheptanyl, and the like.
"3-8 membered heterocyclyl" means a heterocyclic group containing one or more saturated and/or partially saturated rings, including 3 to 8 ring atoms, wherein one or more ring atoms is selected from nitrogen, oxygen, or a heteroatom of s (o) m (wherein m is an integer from 0 to 2), the remaining ring atoms being carbon; for example, propylene oxide, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl.
"halogen" refers to fluorine, chlorine, bromine and iodine.
“C6-C12Aryl "refers to an aromatic ring group containing 6 to 12 ring atoms, but no hetero atom in the ring atoms, preferably a 6-to 10-membered aryl group (i.e., an aryl group having 6 to 10 carbon atoms), such as phenyl or naphthyl.
"5-12 membered heteroaryl" refers to an aromatic cyclic group containing 5-12 ring atoms and 1-4 heteroatoms in the ring atoms as ring members. The heteroatoms may be selected from nitrogen, oxygen or sulfur. The heteroaryl group may be a monocyclic heteroaryl group having 5 to 7 ring atoms, or a bicyclic heteroaryl group having 7 to 12 ring atoms. The bicyclic heteroaryl group may have one ring as long as it is a heteroaromatic ring, and the other ring may be aromatic or non-aromatic, and may or may not contain a heteroatom. In addition, the bicyclic heteroaryl may be a fused ring structure, a spiro ring structure, or two heterocycles may be directly connected. Examples of heteroaryl groups include, but are not limited to, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, pyridyl, pyrimidinyl, furanyl, thienyl, isoxazolyl, indolyl, and the like.
In a second aspect, the present invention provides a method for preparing the phthalazinone derivatives of the present invention, the method comprising the step of subjecting compound III to condensation reaction with acid IV to obtain a compound represented by general formula I, as shown in the following reaction formula:
wherein R, n and Het are as defined above.
The condensation reaction can be carried out in the presence of a base, a condensing agent and a solvent, wherein the solvent is one or a mixture of more of N, N-dimethylformamide, N-dimethylacetamide, dimethyl sulfoxide, dichloromethane, tetrahydrofuran or 1, 4-dioxane, and is preferably N, N-dimethylformamide; the base can be one or more of triethylamine, N-Diisopropylethylamine (DIEA), triethylene diamine, 1, 8-diazabicycloundeca-7-ene (DBU), potassium carbonate, sodium carbonate or sodium bicarbonate, preferably triethylamine; the condensing agent is one or a mixture of more of O- (benzotriazole-1-yl) -N, N, N ', N' -tetramethyluronium Hexafluorophosphate (HBTU), 2- (7-benzotriazole oxide) -N, N, N ', N' -tetramethyluronium Hexafluorophosphate (HATU), 1-hydroxybenzotriazole (HBOt) or 1-hydroxy-7-azobenzotriazol (HOAt), and the HBTU is preferred.
The temperature of the condensation reaction can be 0-100 ℃, and room temperature is preferred, wherein the room temperature is 20-30 ℃;
in a preferred embodiment, the compound of formula IV is prepared by a process comprising: subjecting compound V and compound VI to a Wittig reaction to obtain compound VIII, and then subjecting the compound VIII and the compound VI to a hydrolysis reaction to obtain compound IV,
wherein,
R1is methyl or ethyl;
het and R are as defined above.
The wittig reaction can be carried out in an organic solvent and is carried out at the temperature of about 60-120 ℃. The hydrolysis reaction may be carried out in the presence of a basic solution.
The organic solvent can be one or a mixture of more selected from toluene, xylene, THF and dioxane;
the alkali solution may be one aqueous solution selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.
In a preferred embodiment, the compound of formula III is prepared by a process comprising the steps of: carrying out condensation reaction on a compound shown as a general formula IX and alcohol amine VIII to obtain a compound X; carrying out esterification reaction on the compound X and methylsulfonyl chloride to obtain a compound XI; the compound XI is subjected to substitution reaction in the presence of phthalimide salt, and then is subjected to hydrazinolysis to obtain a compound III, which is shown in the following formula,
wherein n is as defined in formula I.
The condensation reaction may be carried out in the presence of a base, a condensation agent and a solvent.
The esterification reaction may be carried out in the presence of a base and a solvent.
The base in the condensation reaction and the esterification reaction is respectively and independently selected from one or more of triethylamine, N-Diisopropylethylamine (DIEA), triethylene diamine, 1, 8-diazabicycloundece-7-ene (DBU), potassium carbonate, sodium carbonate or sodium bicarbonate, and is preferably triethylamine.
The condensing agent is one or a mixture of more of O- (benzotriazole-1-yl) -N, N, N ', N' -tetramethyluronium Hexafluorophosphate (HBTU), 2- (7-benzotriazole oxide) -N, N, N ', N' -tetramethyluronium Hexafluorophosphate (HATU), 1-hydroxybenzotriazole (HBOt) or 1-hydroxy-7-azobenzotriazol (HOAt), and the HBTU is preferred.
The solvent in the condensation reaction and the esterification reaction is respectively and independently selected from one or a mixture of more of N, N-dimethylformamide, N-dimethylacetamide, dimethyl sulfoxide, dichloromethane, tetrahydrofuran or 1, 4-dioxane, and is preferably N, N-dimethylformamide.
The temperature of the condensation reaction is 0-100 ℃, and the room temperature is preferably selected, wherein the room temperature is 20-30 ℃;
the phthalimide salt is selected from phthalimide potassium salt or phthalimide sodium salt, and is preferably phthalimide potassium salt.
In a third aspect, the present invention also provides a pharmaceutical composition, which comprises a therapeutically effective amount of one or more selected from the group consisting of the phthalazinone derivatives, geometric isomers thereof, and pharmaceutically acceptable salts thereof as an active ingredient, and a pharmaceutically acceptable carrier.
The phthalazinone derivatives represented by the general formula I, geometric isomers and pharmaceutically acceptable salts thereof can be used as cell poly adenosine diphosphate ribose polymerase (PARP) drug-resistance related inhibitors; can be used for preparing medicines for preventing and/or treating diseases related to the drug resistance of poly (adenosine diphosphate ribose) polymerase (PARP); can be used for preparing medicaments for preventing and/or treating cancers; can also be used for preparing medicaments for preventing and/or treating ischemic diseases; or used for preparing medicines for treating neurodegenerative diseases.
By "therapeutically effective amount" is meant: the amount of active ingredient is sufficient to significantly improve the condition without causing serious side effects. Generally, a unit dose of a pharmaceutical composition may contain 1-2000mg of active ingredient, more preferably, 10-200mg of active ingredient. Preferably, the "unit dose" is, for example, a tablet, or a capsule.
The term "pharmaceutically acceptable salt" refers to a salt with an inorganic acid such as phosphoric acid, sulfuric acid, or hydrochloric acid, or an organic acid such as acetic acid, tartaric acid, citric acid, or malic acid, or an acidic amino acid such as aspartic acid or glutamic acid, or a salt with an inorganic base after forming an ester or amide with the above acid, such as sodium, potassium, calcium, aluminum salt, and ammonium salt.
"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of being combined with the active ingredients of the present invention and with each other without significantly diminishing the efficacy of the active ingredient. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate etc.), gelatin, talc, solid lubricants (e.g. stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g. soya oil, sesame oil, peanut oil, olive oil, sesame oil, peanut oil, sesame oil, peanut oil, corn oil, sesame oil, peanut oil, sesame oil, peanut oil, corn oil, sesame oil, corn oilOlive oil, etc.), polyol (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifierWetting agents (such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
The mode of administration of the active ingredient or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and the like.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
In these solid dosage forms, the active ingredient is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
The solid dosage forms may also be prepared using coatings and shells, such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active ingredient in such compositions may be delayed in a certain portion of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, especially cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like. In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active ingredients, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these materials, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
The compounds of the present invention may be administered alone or in combination with other therapeutic agents, such as chemotherapeutic agents.
When the pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is suitable for mammals (such as human beings) to be treated, wherein the administration dose is a pharmaceutically-considered effective administration dose, and for a human body with a weight of 60kg, the daily administration dose is usually 1 to 2000mg, preferably 20 to 1000 mg. Of course, the particular dosage will depend upon such factors as the route of administration, the health of the patient, and the like, and is within the skill of the skilled practitioner.
In a fourth aspect, the invention also provides the use of the phthalazinone derivatives represented by the general formula I, their geometric isomers and pharmaceutically acceptable salts in the preparation of medicaments for preventing or treating diseases associated with poly (adenosine diphosphate ribose) polymerase (PARP) drug resistance.
The diseases related to the drug resistance of poly (adenosine diphosphate ribose) polymerase (PARP) comprise: cancer, various ischemic diseases and neurodegenerative diseases, etc.
The cancer includes, but is not limited to, solid and non-solid tumors, such as breast cancer, ovarian cancer, liver cancer, melanoma, prostate cancer, colon cancer, gastric cancer, lung cancer, glioma, recurrent blood cancer, ewing's sarcoma, pancreatic cancer, endometrial cancer, and the like.
The ischemic diseases include, but are not limited to, ischemic cerebrovascular diseases, coronary heart diseases, ischemic spinal cord diseases, mesenteric vascular ischemic diseases, ischemic retinopathy, ischemic enteritis, etc.
The neurodegenerative disease includes but is not limited to Parkinson's disease, Alzheimer's disease, muscular dystrophy and the like.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
In all of the embodiments described herein, the first,1HNMR were recorded by a nuclear magnetic resonance apparatus of the Varian Mercury-300 or Varian Mercury-400 type, chemical shifts being expressed in δ (ppm); mass spectra were recorded on a Finnigan/MAT-95(EI) and Finnigan LCQ/DECAad Micromass Ultra Q-TOF (ESI) type mass spectrometer; the separation of the compound selects 200-300 mesh silica gel of Qingdao ocean chemical industry.
In the invention, the Chinese name table of the reagent represented by the chemical formula or English letter abbreviation is as follows:
EtOH is ethanol; DCM dichloromethane; MeOH is methanol; NaOH is sodium hydroxide; DMF is N, N-dimethylformamide; THF is tetrahydrofuran; et (Et)3N is triethylamine; MsCl is methanesulfonyl chloride and DBU is 1, 8-diazabicycloundec-7-ene.
Preparation of intermediates
A) Preparation method of key intermediate compound III-1
Route 2
Step 1 preparation of Compound X-1
Compound IX-1(5.96g,20.0mmol) and compound 4(3.14g,20.0mmol) were added to a three-necked reaction flask containing anhydrous DMF (100mL) under nitrogen, followed by HBTU (8.3g,22.0mmol) and triethylamine (4.0g,40.0mmol) at 25 ℃ until the main starting compound 1 was substantially disappeared. The reaction was then poured into ice water (800mL), the combined system was extracted with DCM (200mL × 3), the DCM phase was washed with saturated sodium chloride solution, dried and concentrated to give the crude product. The crude product was flash chromatographed (200-300 mesh silica gel with DCM: MeOH: 100: 1-40: 1, v/v mobile phase) to afford compound X-17.4g, 83% yield.1H-NMR(300Hz,DMSO-d6)δ:12.58(s,1H),8.251(d,J=7.5Hz,1H),7.96(d,J=7.5Hz,1H),7.86(m,2H),7.40(brs,1H),7.28(d,J=6.6Hz,1H),7.20(t,1H),4.45(brs,1H),4.34(s,3H),3.38(q,2H),2.93(m,1H),2.70(m,1H),1.73(d,1H),1.40(m,4H);MS(ESI):438.2m/z[M+H]+。
Step 2: preparation of Compound XI-1
Compound X-1(7.0g,16.0mmol) was dissolved in DCM (100mL) and Et was added3N (3.2g,32.0mmol) and cooling the reaction to about 0 deg.C, a solution of MsCl (1.9g,16.8mmol) in DCM (10.0mL) was slowly added dropwise, the temperature was controlled below 50 deg.C until the starting material completely disappeared by stirring at room temperature. And then adding a saturated citric acid solution for washing, then washing with a saturated sodium bicarbonate solution and a saturated sodium chloride solution, drying and concentrating to obtain a crude product. The crude product was flash chromatographed (200-300 mesh silica gel with DCM: MeOH: 800: 1-40: 1, v/v mobile phase) to give compound XI-17.2g, 87.8% yield.
1H-NMR(400Hz,DMSO-d6)δ:12.59(s,1H),8.24(d,J=8Hz,1H),7.94(d,J=8Hz,1H),7.92~7.88(m,2H),7.39(brs,1H),7.27(d,J=6.4Hz,1H),7.19(t,1H),4.43(d,J=12.8Hz,1H),4.31(s,1H),3.62(t,2H),3.31(s,3H),3.05~3.10(q,2H),2.93(t,1H),2.69~2.72(m,1H),1.65~1.72(m,3H),1.45(brs,2H),1.32~1.38(q,2H),1.14~1.17(t,4H),0.94~1.04(m,1H).MS(ESI):m/z 516.2[M+H]+。
And step 3: preparation of Compound III-1
Compound XI-1(6.28g,12.2mmol) and phthalimide potassium salt (2.7g,14.6mmol) were dissolved in anhydrous DMF (50.0mL) at room temperature, then the reaction was heated to an internal temperature of 90 ℃ to react until the main starting material was reacted completely, and cooled to room temperature. The reaction was poured into ice water (200mL) and stirred, DCM (50mL × 3) was added for extraction, the DCM phase was washed with saturated sodium chloride solution, dried and concentrated to give the crude product. The crude product was flash chromatographed (200-300 mesh silica gel with DCM: MeOH: 80: 1-20: 1, v/v mobile phase) to afford 2.8g of intermediate in 40% yield.
The intermediate (2.6g,4.6mmol) obtained in the above step and 80% hydrazine hydrate (0.6mL,23.0mmol) were added to 95% ethanol (50.0mL), and then the reaction system was warmed to reflux state until the main raw material was completely disappeared, a white solid was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. The crude product is flash chromatographed (200-300 mesh silica gel with DCM: MeOH: 20: 1-10: 1, v/v mobile phase) to give compound III-10.9g, 45% yield.1H-NMR(300Hz,DMSO-d6)δ:8.26(d,J=7.8Hz,1H),8.02~8.05(m,1H),7.690(d,J=7.8Hz,1H),7.77~7.90(m,2H),7.39~7.43(q,1H),7.42(d,J=6.6Hz,1H),7.21(t,1H),4.44(d,J=15.3Hz,1H),4.32(s,1H),3.19~3.27(m,1H),2.92(t,1H),2.60~2.73(m,2H),1.70~1.76(m,,1H),1.39~1.43(m,4H),1.17~1.27(m,5H),0.83~1.01(m,2H).MS(ESI)m/z:437.0[M+H]+。
B) The compounds VII-1 to VII-22 can be obtained by direct purchase or by the following scheme (scheme 3)
Route 3
Wherein as described in Table 1, is prepared byMiddle query, compounds VII-1 to VII-22 except three compounds vii-8, vii-15 and vii-17 without CAS number [ remarks: TABLE 1 CAS numbers for only non-single isomers ] the present invention provides a scheme for the preparation of intermediates VII-8, VII-15 and VII-17, other intermediates being commercially available or prepared by methods referred to for VII-8.
TABLE 1 substituted acrylic Compounds VII-1 to VII-22
Process for the preparation of intermediates VII-8, VII-15 and VII-17
1) Preparation of Compound VII-8:
n- (5-formyl-4- (trifluoromethyl) pyridin-2-yl) pivaloamide (548mg,2.0mmol) and methoxycarbonylmethylenetriphenylphosphine (734.8mg,2.2mmol) were added to toluene (20.0mL) at 100 ℃ to react until the aldehyde was completely disappeared, the toluene was concentrated to remove, silica gel was added, and the mixture was stirred with petroleum ether: the column was filtered through ethyl acetate 15:1 to 8:1 to give 630mg of methyl 3- (6-pivaloylamino-4- (trifluoromethyl) pyridin-3-yl) acrylate as a white solid.1H-NMR(300Hz,CDCl3)δ:8.64(s,1H),8.61(s,1H),8.21(s,1H),7.90(d,J=15.9Hz,1H),6.43(d,J=15.9Hz,1H),3.83(s,3H);ESI(m/z):331.0[M+1]+
Methyl 3- (6-pivaloylamino-4- (trifluoromethyl) pyridin-3-yl) acrylate (344mg,1.0mmoL) was dissolved in 95% ethanol (50mL) and sodium hydroxide (400mg,10.0mmoL) was added and the reaction was allowed to proceed under reflux until hydrolysis of the starting material was complete. Concentrating to remove ethanol, adding water, adjusting pH to about 5 with dilute hydrochloric acid, precipitating to obtain a large amount of solid, filtering to obtain solid, and drying to obtain 230mg of compound VII-8.1H-NMR(300Hz,CDCl3)δ:8.64(s,1H),8.61(s,1H),8.21(s,1H),7.90(d,J=15.9Hz,1H),6.43(d,J=15.9Hz,1H);ESI(m/z):233.0[M+1]+。
2) Preparation of Compound VII-15
6- (ethylamino) nicotinaldehyde (225mg,1.5mmol) and methoxycarbonylmethylenetriphenylphosphine (551mg,1.65mmol) were added to toluene (20.0mL) at 100 ℃ to react until the aldehyde completely disappeared, the toluene was concentrated off, silica gel was added, and the mixture was stirred with petroleum ether: ethyl acetate 15: 1-8: 1, v/v, and column chromatography gave 240mg of methyl 3- (6- (ethylamino) pyridin-3-yl) acrylate as a white solid.1H-NMR(300Hz,CDCl3)δ:8.19(d,J=2.4Hz,1H),7.64(d,J=2.4Hz,0.5H),7.61(s,1H),7.55(s,0.5H),6.38(d,J=8.7Hz,1H),6.21(d,J=15.9Hz,1H),3.78(s,3H),3.36(q,2H),1.27(t,3H);ESI(m/z):207.1[M+1]+。
Adding reaction residue of methyl 3- (6- (ethylamino) pyridin-3-yl) acrylate (206mg,1.0mmol) into 95% ethanol (10mL), adding sodium hydroxide (400mg,10mmol) under reflux to react until the reaction of the raw materials is complete, concentrating to remove ethanol, adding water, adjusting pH to about 5 with dilute hydrochloric acid, precipitating a large amount of solid, filtering to obtain a solid, and drying to obtain 110mg of compound VII-15.1H-NMR(300Hz,CDCl3)δ:8.19(d,J=2.4Hz,1H),7.64(d,J=2.4Hz,0.5H),7.61(s,1H),7.55(s,0.5H),6.38(d,J=8.7Hz,1H),6.21(d,J=15.9Hz,1H),3.36(q,2H),1.27(t,3H);ESI(m/z):193.1[M+1]+。
3) Preparation of Compound VII-17
6-chloronicotinaldehyde (560mg,4.0mmol) and ethyl 2- (triphenylphosphine ylidene) propionate (1.33g,4.4mmol) were added to toluene (20.0mL) and reacted at 100 ℃ until the aldehyde completely disappeared, the toluene was concentrated off, silica gel was added, and the mixture was stirred with petroleum ether: ethyl acetate 15: 1-8: 1, v/v, and the column was passed to give 896mg of methyl 3- (6-chloropyridin-3-yl) acrylate as a white solid.1H-NMR(300Hz,DMSO-d6)δ:8.52(d,J=2.7Hz,1H),8.00(dd,J=0.6Hz,8.1Hz),7.59(d,J=6.9Hz,1H),7.58(s,1H),4.18~4.25(q,2H),2.04(d,J=1.5Hz,3H),1.27(t,3H);ESI(m/z):212.1[M+1]+。
Adding reaction residue of 3- (6-chloropyridin-3-yl) methyl acrylate (422mg,2.0mmol) into 95% ethanol (20mL), adding sodium hydroxide (800mg,20mmol) under reflux for reaction until the raw materials react completely, concentrating to remove ethanol, adding water, adjusting pH to about 5 with dilute hydrochloric acid, precipitating a large amount of solid, filtering to obtain a solid, and drying to obtain 315mg of compound VII-17.
1H-NMR(300Hz,DMSO-d6)δ:12.76(s,1H),8.52(d,J=2.7Hz,1H),7.98(dd,J=8.4Hz,2.7Hz,1H),7.57~7.60(m,2H),2.02(d,J=1.2Hz,3H);ESI(m/z):198.1[M+1]+。
Preparation example
Preparation method and data analysis of compounds I-1 to I-22
Compound III-1(1.5mmol,1eq) and the corresponding compound IV (1.65mmol,1.1eq) were dissolved in DMF (10mL) and stirred, followed by the addition of HBTU (1.8mmol,1.2eq) and triethylamine (2.25mmol,1.5eq) and reaction at room temperature until compound III-1 was completely reacted. The reaction was poured into ice water and extracted with DCM to give an organic phase. The DCM phase was washed with brine, dried over anhydrous sodium sulfate, and passed through silica gel (200-300 mesh) column to obtain the corresponding compounds, the specific data are shown in table 2 below.
Table 2: mass and nuclear magnetic data of Compounds I-1 to I-22
Test example
Activity test experiment of Compounds I-1 to I-22
Methods and sources for primary reagent production
The culture medium for various tumor cells is derived from Gibco, CCK-8 is derived from Dongnan chemical, nicotinamide adenine dinucleotide NAD+Purchased from sigma, DNA purchased from Shanghai biosynthesis, Histone purchased from Yuanshigen, Anti-PAR Polycolonal Antibody (rabbit) purchased from Trevigen, Goat Anti-rabbitlgG-HRP purchased from Jackson, 96 well plate purchased from corning, Tris (hydroxymethyl) aminomethane (Tris-HCL) and Tween purchased from national pharmaceutical group reagents, magnesium chloride (MgCl)2) Bovine Serum Albumin (BSA), and o-phenylenediamine (OPD) were purchased from bioengineering (shanghai) gmbh, and the positive control compound olaparib (AZD2281) was purchased from LC lab.
Test example 1
Experiment on PARP molecule level inhibition and cell proliferation inhibition
The experimental method comprises the following steps: Enzyme-Linked immunosorbent assay (ELISA) (reference: Decker, P.; Miranda, E.A.; de Murcia, G.and Muller, S.A. and improved nonosonic test to screen a large series of new inhibitors of poly (ADP-ribose) polymerase activity for therapeutic applications, Clin. cancer Res.1999,5, 9-. The principle is that the substrate histone is coated on an adsorptive 96-well plate, and PARP1 recombinase and substrate NAD are added+The PARP1 enzyme activity can be reflected by the fact that PARP1 is enzymatically reacted by activated DNA to produce a product PAR (poly-adenosine-diphosphate ribose) by histone, then an antibody against PAR (anti-PAR) is added, and the strength of the product PAR on the histone coated on a 96-well plate is detected.
For detailed procedures of the experiment and preparation of reagents used, such as reaction buffers and buffers, reference is made to TREVIGENHTF instructions for the homologous poly (adenosine diphosphate-nucleic acid) polymerase inhibition kit.
The experimental operation steps are as follows:
1. histone (3 ng/well) was immobilized on absorbent 96-well plates in phosphate buffer (150mM NaCl, 7.7mM Na phosphate disodium dodecahydrate2HPO4·12H2O, 2.3mM sodium dihydrogen phosphate dihydrate NaH2PO4·2H2O, pH8.0), 100 mu L/hole, shaking overnight at 37 ℃;
2. washing with phosphate buffer containing 0.2 wt.% Tween-20 for three times, and oven drying;
3. dissolving the compound to be tested in dimethyl sulfoxide, and then diluting with phosphate buffer to the inhibitor of the concentration required by the experiment; then nicotinamide adenine dinucleotide (PARP1 enzyme system plus 0.8. mu.M/well) (PARP2 enzyme system plus 26. mu.M/well), DNA (100 ng/well), PARP1/2 enzyme (10 ng/well) (reaction buffer 50mM Tris, 2mM MgCl2pH8.0 dilution), adding inhibitor with a certain dilution concentration of 10 μ L into each well, setting each concentration for 2 times, reacting in 100 μ L/well (supplemented with reaction buffer solution), shaking table reacting at 37 deg.C for 1.5 hr, and setting blank, positive and negative controls;
4. washing with 0.2 wt.% Tween-20 in phosphate buffer for three times, adding anti-PAR polyclonal antibody (1: 6000, diluted with 5mg/mL bovine serum albumin in 0.2% Tween-20 in phosphate buffer), 100. mu.L/well, and incubating at 37 ℃ for 1.5 hours in a shaker;
5. washing with phosphate buffer containing 0.2 wt.% Tween-20 for three times, and performing shaking reaction on goat anti-rabbit antibody (1: 2000 diluted with 5mg/mL bovine serum albumin in phosphate buffer containing 0.2 wt.% Tween-20) labeled with horseradish peroxidase at 100 μ L/well at 37 deg.C for 1 hr;
6. washed three times with phosphate buffer containing 0.2 wt.% tween-20, 2mg/mL o-phenylenediamine (i.e., OPD, formulated with 5mM citric acid in sodium citrate buffer, 15mM sodium citrate) was added 0.1% of 30% H2O2100 mu L/hole, reacting for 5-15 minutes;
7. with 50. mu.L of 2M H2SO4Termination is inverseOD was measured at 490 nm.
The experimental observation indexes are as follows:
OD was measured at 490nm wavelength using a microplate reader (VERSAmax).
And (3) judging and explaining the experimental results:
inhibition rate ═ 100% (control OD value-administration OD value-blank OD value)/(control OD value-blank OD value) ×
The compounds were set up for 6 concentration gradients and IC calculated50。
The experimental results are as follows: compounds were evaluated for inhibition of PARP1/2 using olaparib (AZD2281) as a positive control, and the results are shown in table 3 using a 10-fold dilution of 1 μ M with 6 concentration gradients on PARP1 and PARP2 enzymes.
TABLE 3 inhibition of PARP molecular level and inhibition of cell proliferation by Compounds I-1 to I-22
Test example 2
Experiment of inhibition effect of partial compounds on MDA-MB-436 parent and drug-resistant cell proliferation
The experimental method comprises the following steps: the proliferation inhibition effect and the proliferation inhibition degree of the compound are compared by using a Cell proliferation toxicity detection Kit (CCK-8) method for BRCA 1-deficient human breast cancer MDA-MB-436 parent cells and Olaparib (AZD2281) drug-resistant cells.
The experimental operation steps are as follows:
1. cells in logarithmic growth phase were seeded at 180. mu.L/well in 96-well culture plates and cultured at 37 ℃ for 18 hours until the cells adhered.
2. 20 μ L of drug at a dilution concentration was added to each well in triplicate for each concentration. And setting physiological saline solvent control and cell-free zero setting holes with corresponding concentrations, and making cell-free zero setting holes with corresponding drug concentrations if the drugs are colored.
3. Tumor cells were incubated at 37 ℃ with 5% CO2Cultured for 7 days under the condition.
4. Adding 10 mu L of CCK-8 solution per well, and continuing culturing for 3-5 hours (controlling the OD value to be about 1.0).
5. And measuring an OD450 value by using a microplate reader.
The experimental observation indexes are as follows: OD was measured at a wavelength of 450nm using a microplate reader (VERSAmax).
And (3) judging and explaining the experimental results:
calculating the inhibition rate of the tested substance on the growth of cancer cells, half inhibition IC according to the following formula50The values were calculated using the Logit method.
Inhibition rate (control OD value-administration OD value)/control OD value × 100%
The compounds were set up for 6 concentration gradients and IC calculated50。
The experimental results are as follows: and (3) evaluating the proliferation inhibition of partial compounds on MDA-MB-436 parent and AZD2281 drug-resistant strain pair cells by taking AZD2281 as a positive control, and performing 5-fold dilution on 50 mu M in an experiment to act on the cells with 6 concentration gradients for 7 days. Computing IC50The results are shown in Table 4.
TABLE 4 proliferation inhibition of a subset of compounds on MDA-MB-436 parent and AZD2281 drug-resistant strains on cells
As can be seen from Table 4, the proliferation inhibition of MDA-MB-436/AZD2281 resistant cells by most compounds was better than that of AZD 2281.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Claims (14)
1. A phthalazinone derivative shown as a general formula I and pharmaceutically acceptable salts thereof,
wherein,
r is selected from H and C1-C6An alkyl group;
n is an integer of 1-6;
het is selected from substituted or unsubstituted naphthyl, substituted or unsubstituted five-membered heteroaryl, substituted or unsubstituted six-membered heteroaryl, substituted or unsubstituted five-membered and six-membered heteroaryl, wherein the heteroaryl contains 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur in a ring atom; the substituted substituent is selected from halogen, nitryl, amino, cyano, hydroxyl and C1-C6Alkyl radical, C1-C6Alkoxy, halo C1-C6Alkyl, hydroxy C1-C6Alkyl radical, C1-C6Alkylamino, di-C1-C6One or more of an alkylamino group and a 3-8 membered heterocyclyl group, wherein one or more ring atoms of the heterocyclyl group are selected from heteroatoms of nitrogen, oxygen and sulfur.
2. The phthalazinone derivatives of formula I and pharmaceutically acceptable salts thereof as claimed in claim 1, wherein,
r is selected from H, methyl and ethyl;
n is an integer of 2 to 5.
4. The phthalazinone derivative of formula I as claimed in any one of claims 1 to 3, wherein,
the substituted substituent is selected from halogen, nitryl, amino, cyano, hydroxyl and C1-C6Alkyl radical, C1-C6Alkoxy, halo C1-C6Alkyl, hydroxy C1-C6Alkyl radical, C1-C6Alkylamino, di-C1-C6One or more of alkylamino, pyrrolidinyl, piperidinyl, and morpholinyl.
5. The phthalazinone derivative of formula I as claimed in any one of claims 1 to 3, wherein,
het is substituted or unsubstituted indolyl, substituted or unsubstituted naphthyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidyl or
Wherein X is selected from O, N or S;
Y1and Y2Each independently selected from N or C, both not simultaneously N,
the substituted substituent is selected from halogen, nitryl, amino, cyano, hydroxyl and C1-C4Alkyl radical, C1-C6Alkoxy, halogen-substituted C1-C4Alkyl, morpholinyl, piperidinyl, pyrrolidinyl and C1-C4One or more of alkylamino groups.
6. The phthalazinone derivative of formula I as claimed in any one of claims 1 to 3, wherein,
het is selected from pyridyl, chloropyridyl, indolyl, pyrrolyl, thiazolyl, pyrimidinyl, aminotrifluoromethylpyridyl, azaindolyl, dimethylisoxazolyl, piperidinyl pyridyl, morpholinyl pyridyl, pyrrolidino pyridyl, diethylamino pyridyl, ethylamino pyridyl, methylaminopyridyl, naphthyl, aminopyridyl, benzofuranyl.
7. The phthalazinone derivative of formula I as claimed in any one of claims 1 to 3, wherein,
het is selected from 4-pyridyl, 2-chloro-5-pyridyl, 3-indolyl, 2-pyrrolyl, 4-thiazolyl, 5-pyrimidinyl, 2-amino-6- (trifluoromethyl) -5-pyridyl, 7-azaindolyl, 3, 5-dimethyl-4-isoxazolyl, 2-piperidinyl-5-pyridyl, 2-morpholinyl-5-pyridyl, 2-pyrrolidin-5-pyridyl, 2-diethylamino-5-pyridyl, 2-ethylamino-5-pyridyl, 2-methylamino-5-pyridyl, 1-naphthyl, 6-azaindolyl, 2-pyridyl, 5-pyridyl, 2-pyridyl, etc, 2-amino-5-pyridyl, 3-benzofuranyl and 3-pyridyl.
10. A pharmaceutical composition comprising a therapeutically effective amount of one or more selected from the phthalazinone derivatives and pharmaceutically acceptable salts thereof as claimed in any one of claims 1 to 8 as an active ingredient, and a pharmaceutically acceptable carrier.
11. Use of the phthalazinone derivative according to any one of claims 1-8 and pharmaceutically acceptable salts thereof or the pharmaceutical composition according to claim 10 for preparing a medicament for preventing or treating diseases related to poly (adenosine diphosphate ribose) polymerase resistance.
12. The use of claim 11, wherein the disease associated with poly (adenosine diphosphate ribose) polymerase resistance comprises: cancer, ischemic diseases and neurodegenerative diseases.
13. The use of claim 12, wherein the cancer comprises solid and non-solid tumors, and the ischemic disease comprises ischemic cerebrovascular disease, coronary heart disease, spinal cord ischemic disease, mesenteric vascular ischemic disease, ischemic retinopathy and ischemic enteritis; the neurodegenerative disease comprises Parkinson's disease, Alzheimer's disease and muscular dystrophy.
14. The use according to claim 12, wherein the cancer is selected from breast cancer, ovarian cancer, liver cancer, melanoma, prostate cancer, colon cancer, gastric cancer, lung cancer, glioma, recurrent hematological cancer, ewing's sarcoma, pancreatic cancer, endometrial cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810162895.7A CN110194762B (en) | 2018-02-27 | 2018-02-27 | Phthalazinone derivatives, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810162895.7A CN110194762B (en) | 2018-02-27 | 2018-02-27 | Phthalazinone derivatives, preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110194762A CN110194762A (en) | 2019-09-03 |
CN110194762B true CN110194762B (en) | 2021-09-10 |
Family
ID=67751260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810162895.7A Expired - Fee Related CN110194762B (en) | 2018-02-27 | 2018-02-27 | Phthalazinone derivatives, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110194762B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113288892B (en) * | 2020-02-24 | 2024-04-26 | 甫康(上海)健康科技有限责任公司 | Use of poly ADP-ribose polymerase inhibitors against coronaviruses |
BR112022025057A2 (en) * | 2020-06-12 | 2023-01-31 | Shanghai Jemincare Pharmaceuticals Co Ltd | PHTHALAZINONE COMPOUND AND METHOD OF PREPARATION AND MEDICAL USE THEREOF |
CN116323619A (en) * | 2021-05-26 | 2023-06-23 | 因诺库尔治疗公司 | Piperidinedione derivatives |
CN113788827B (en) * | 2021-10-18 | 2023-04-25 | 中国药科大学 | Phthalazinone compound, preparation method and medical application thereof |
CN116143700B (en) * | 2022-12-08 | 2024-06-28 | 沈阳药科大学 | Phthalazinone compound, and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1788000A (en) * | 2003-03-12 | 2006-06-14 | 库多斯药物有限公司 | Phthalazinone derivatives |
CN107629071A (en) * | 2016-07-19 | 2018-01-26 | 上海勋和医药科技有限公司 | Substitution 2,4(1H,3H)Hybar X is as PARP inhibitor and its application |
-
2018
- 2018-02-27 CN CN201810162895.7A patent/CN110194762B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1788000A (en) * | 2003-03-12 | 2006-06-14 | 库多斯药物有限公司 | Phthalazinone derivatives |
CN107629071A (en) * | 2016-07-19 | 2018-01-26 | 上海勋和医药科技有限公司 | Substitution 2,4(1H,3H)Hybar X is as PARP inhibitor and its application |
Also Published As
Publication number | Publication date |
---|---|
CN110194762A (en) | 2019-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110194762B (en) | Phthalazinone derivatives, preparation method and application thereof | |
TWI757256B (en) | Inhibitors of ret | |
TWI725266B (en) | FGFR4 inhibitor, its preparation method and pharmaceutical application | |
CN105524048B (en) | As the indazole compounds of FGFR kinase inhibitor and its preparation and application | |
ES2833576T3 (en) | Novel glutaminase inhibitors | |
WO2018121228A1 (en) | Compound having axl inhibitory activity, preparation method therefor and use thereof | |
TWI527800B (en) | 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof | |
CN104003940B (en) | 2,4-difluoro-5-( phthalazone-1-methyl)-benzoyl piperazine compound and application thereof | |
CN109983016B (en) | Pyrimido [5,4-b ] indolizine or pyrimido [5,4-b ] pyridine compound, preparation method and application thereof | |
CA2864672C (en) | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | |
CN102675286B (en) | One class indazole compounds and preparation method thereof, purposes and pharmaceutical composition | |
CN106810536A (en) | A kind of kinases inhibitor and preparation method thereof and medical usage | |
US9156853B2 (en) | AKT inhibitor compounds for treatment of cancer | |
TW201731841A (en) | 6-aryl or 6-heteroaryl 4-morpholin-4-yl-pyridine-2-one compounds | |
CN112979679B (en) | Fluoroheterocyclic derivative having macrocyclic structure and use thereof | |
JP7254094B2 (en) | Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors | |
JP2015508775A5 (en) | ||
CN117362323A (en) | PRMT5 inhibitor and application thereof | |
CN110691775B (en) | Aldehyde pyridine derivative with FGFR4 inhibitory activity, and preparation method and application thereof | |
CN110407806B (en) | Carboxamide compounds, preparation method and application thereof | |
CN117510503A (en) | Tyrosine threonine kinase PKMYT1 inhibitor | |
CN109384785B (en) | Pyrrolopyridinone derivatives, preparation method and medical application thereof | |
WO2019029554A1 (en) | Sulfonamide derivative, preparation method thereof, and use of same in medicine | |
JP2024526096A (en) | Novel compounds as protein kinase inhibitors | |
CN106146468B (en) | Pyridone protein kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210910 |
|
CF01 | Termination of patent right due to non-payment of annual fee |